Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-27 03:00 | 2025-06-24 | KALA | KALA BIO, Inc. | Reumuth Mary | Officer | SELL | $4.01 | 3,631 | $14,560 | 62,100 |
| 2025-06-27 03:00 | 2025-06-24 | KALA | KALA BIO, Inc. | Bazemore Todd | Officer | SELL | $4.01 | 4,058 | $16,273 | 83,699 |
| 2025-06-27 00:26 | 2025-06-24 | AGIO | Agios Pharmaceuticals Inc. | Burns James William | Officer | OPT+S | $33.54 | 2,799 | $93,878 | 28,650 |
| 2025-06-27 00:25 | 2025-06-24 | AGIO | Agios Pharmaceuticals Inc. | Gheuens Sarah | Officer | OPT+S | $33.54 | 2,909 | $97,568 | 56,988 |
| 2025-06-27 00:24 | 2025-06-24 | AGIO | Agios Pharmaceuticals Inc. | Jones Cecilia | Officer | OPT+S | $33.54 | 1,780 | $59,701 | 30,049 |
| 2025-06-27 00:23 | 2025-06-24 | AGIO | Agios Pharmaceuticals Inc. | Milanova Tsveta | Officer | OPT+S | $33.54 | 2,770 | $92,906 | 26,122 |
| 2025-06-27 00:22 | 2025-06-24 | AGIO | Agios Pharmaceuticals Inc. | Goff Brian | Director, Officer | OPT+S | $33.54 | 18,700 | $627,198 | 111,922 |
| 2025-06-27 03:00 | 2025-06-24 | KALA | KALA BIO, Inc. | Iwicki Mark T | Director | SELL | $4.01 | 13,227 | $53,040 | 258,433 |
| 2025-06-27 02:41 | 2025-06-24 | NAMS | NewAmsterdam Pharma Co N.V. | Topper James N | Director | BUY | $18.38 | 3,780 | $69,466 | 3,026,133 |
| 2025-06-27 03:00 | 2025-06-24 | KALA | KALA BIO, Inc. | Brazzell Romulus K | Officer | SELL | $4.01 | 5,251 | $21,057 | 82,698 |
| 2025-06-27 00:08 | 2025-06-24 | BBIO | BridgeBio Pharma, Inc. | MCCORMICK FRANK | Director | SELL | $44.23 | 100,000 | $4,422,800 | 879,979 |
| 2025-06-27 03:00 | 2025-06-24 | CYRX | Cryoport, Inc. | SHELTON JERRELL | Director, Officer | OPT+S | $7.06 | 16,344 | $115,366 | 912,419 |
| 2025-06-27 03:00 | 2025-06-24 | CYRX | Cryoport, Inc. | Mandalam Ramkumar | Director | OPT+S | $7.02 | 13,321 | $93,447 | 73,056 |
| 2025-06-26 02:43 | 2025-06-24 | CNTA | Centessa Pharmaceuticals plc | HUSSAIN IQBAL J | Officer | OPT+S | $14.02 | 12,000 | $168,218 | 105,386 |
| 2025-06-26 02:42 | 2025-06-24 | CNTA | Centessa Pharmaceuticals plc | Accardi Mario Alberto | Officer | OPT+S | $14.00 | 15,000 | $210,000 | 216,485 |
| 2025-06-26 01:08 | 2025-06-25 | TERN | Terns Pharmaceuticals, Inc. | Burroughs Amy L. | Director, Officer | BUY | $3.87 | 23,314 | $90,230 | 47,083 |
| 2025-06-26 00:09 | 2025-06-23 | ONC | BeOne Medicines Ltd. | Wang Lai | Officer | SELL | $260.00 | 1,028 | $267,280 | 0 |
| 2025-06-26 00:08 | 2025-06-23 | ONC | BeOne Medicines Ltd. | Wu Xiaobin | Officer | SELL | $260.00 | 1,363 | $354,380 | 0 |
| 2025-06-26 00:08 | 2025-06-24 | ONC | BeOne Medicines Ltd. | Wang Xiaodong | Director | SELL | $265.50 | 2,007 | $532,867 | 0 |
| 2025-06-26 01:49 | 2025-06-23 | OKUR | OnKure Therapeutics, Inc. | Leverone Jason A. | Officer | SELL | $2.38 | 303 | $722 | 12,906 |
| 2025-06-26 01:52 | 2025-06-23 | OKUR | OnKure Therapeutics, Inc. | Saccomano Nicholas A | Director, Officer | SELL | $2.38 | 88 | $210 | 3,594 |
| 2025-06-25 23:30 | 2025-06-23 | AKTX | Akari Therapeutics Plc ADR | Gaslightwala Abizer | Director, Officer | BUY | $1.16 | 6,146 | $7,120 | 277,574 |
| 2025-06-26 02:44 | 2025-06-25 | CNTA | Centessa Pharmaceuticals plc | Weinhoff Gregory M | Officer | OPT+S | $13.86 | 10,000 | $138,642 | 122,279 |
| 2025-06-26 03:07 | 2025-06-23 | VERA | Vera Therapeutics, Inc. | ENRIGHT PATRICK G | Director | BUY | $21.11 | 250,000 | $5,277,300 | 3,596,593 |
| 2025-06-25 23:18 | 2025-06-23 | INSM | INSMED Inc | Bonstein Sara | Officer | OPT+S | $101.78 | 57,765 | $5,879,091 | 93,536 |
| 2025-06-25 23:38 | 2025-06-24 | UTHR | UNITED THERAPEUTICS Corp | Mesa Nilda | Director | SELL | $289.99 | 645 | $187,045 | 4,883 |
| 2025-06-25 23:36 | 2025-06-24 | UTHR | UNITED THERAPEUTICS Corp | Giltner Richard | Director | OPT+S | $289.60 | 3,036 | $879,214 | 19,384 |
| 2025-06-26 00:06 | 2025-06-23 | ONC | BeOne Medicines Ltd. | OYLER JOHN | Director, Officer | SELL | $261.61 | 3,174 | $830,360 | 0 |
| 2025-06-26 00:01 | 2025-06-23 | AIMD | Ainos Inc. | Taiwan Carbon Nano Technology Corp | 10% owner | SELL | $0.00 | 29,476 | $0 | 5,470,524 |
| 2025-06-25 13:03 | 2025-06-23 | AIMD | Ainos Inc. | ASE Test, Inc. | 10% owner | BUY | $0.00 | 29,476 | $0 | 58,887 |
| 2025-06-25 03:29 | 2025-06-23 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | Officer | SELL | $114.08 | 500 | $57,042 | 31,903 |
| 2025-06-25 00:14 | 2025-06-20 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% owner | BUY | $7.99 | 5,603 | $44,768 | 2,981,806 |
| 2025-06-24 16:01 | 2025-06-20 | IMRX | Immuneering Corp | Hall Brett Matthew | Officer | BUY | $2.58 | 13,422 | $34,617 | 359,318 |
| 2025-06-24 15:52 | 2025-06-20 | IMRX | Immuneering Corp | Brakewood Harold Eugene | Officer | BUY | $2.53 | 1,900 | $4,804 | 5,800 |
| 2025-06-25 01:33 | 2025-06-23 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | Officer | SELL | $10.49 | 33,500 | $351,385 | 68,317 |
| 2025-06-25 00:36 | 2025-06-20 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Officer | SELL | $21.40 | 12,500 | $267,458 | 965,188 |
| 2025-06-24 23:00 | 2025-06-20 | MRUS | Merus N.V. | Silverman Peter B. | Officer | OPT+S | $52.76 | 34,000 | $1,793,840 | 0 |
| 2025-06-25 04:01 | 2025-06-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $11.45 | 100,000 | $1,145,000 | 1,462,223 |
| 2025-06-24 23:08 | 2025-06-24 | ARVN | Arvinas Inc. | Saik Andrew | Officer | SELL | $7.61 | 5,700 | $43,377 | 164,401 |
| 2025-06-25 01:08 | 2025-06-20 | QURE | uniQure N.V. | Springhorn Jeremy P. | Director | SELL | $14.45 | 2,112 | $30,518 | 37,694 |
| 2025-06-25 00:50 | 2025-06-20 | QURE | uniQure N.V. | Jacques Rachelle Suzanne | Director | SELL | $14.45 | 2,112 | $30,518 | 28,346 |
| 2025-06-25 00:45 | 2025-06-20 | QURE | uniQure N.V. | Gut Robert | Director | SELL | $14.45 | 3,336 | $48,205 | 56,879 |
| 2025-06-25 00:42 | 2025-06-20 | QURE | uniQure N.V. | Balachandran Madhavan | Director | SELL | $14.45 | 2,112 | $30,518 | 37,697 |
| 2025-06-25 00:34 | 2025-06-20 | QURE | uniQure N.V. | Meek David D. | Director | SELL | $14.45 | 2,112 | $30,518 | 34,190 |
| 2025-06-24 23:30 | 2025-06-20 | AKTX | Akari Therapeutics Plc ADR | Gaslightwala Abizer | Director, Officer | BUY | $1.20 | 10,000 | $12,000 | 271,428 |
| 2025-06-24 23:39 | 2025-06-20 | VSTM | Verastem, Inc. | Paterson Dan | Director, Officer | SELL | $5.13 | 17,808 | $91,355 | 443,839 |
| 2025-06-24 23:37 | 2025-06-20 | VSTM | Verastem, Inc. | Calkins Daniel | Officer | SELL | $5.13 | 4,135 | $21,202 | 109,920 |
| 2025-06-24 19:41 | 2025-06-24 | RZLT | Rezolute, Inc. | Evans Daron | Officer | BUY | $4.05 | 5,000 | $20,250 | 268,900 |
| 2025-06-25 00:53 | 2025-06-20 | QURE | uniQure N.V. | Kaye Jack | Director | SELL | $14.45 | 2,112 | $30,518 | 20,439 |
| 2025-06-25 01:03 | 2025-06-20 | QURE | uniQure N.V. | POST LEONARD E | Director | SELL | $14.45 | 2,112 | $30,518 | 29,937 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.